Can Nanoparticle-Based Saracatinib Improve Outcomes in Head and Neck Cancer?
Posted: Wednesday, March 6, 2019
According to research published in the Journal of Hematology & Oncology, the blockade of nonreceptor tyrosine kinase Src activity by the inhibitor saracatinib suppressed metastasis of head and neck squamous cell carcinoma. The study also found that a nanoparticle-based drug delivery system may increase the effectiveness of the inhibitor without systemic toxicity.
“We spent more than 3 years on developing Src-based nanomedicine to suppress the development and metastasis of head and neck cancer, which has a significant impact on cancer treatment,” Yong Teng, PhD, of Augusta University, Georgia, told JNCCN 360.
Through mechanistic assessment, Dr. Teng and colleagues found that saracatinib prompted suppression of Src-dependent invasion or metastasis by downregulating the expression of Vimentin and Snail proteins. In an experimental metastasis mouse model, saracatinib loaded into multifunctional nanoparticles was more effective in suppressing head and neck squamous cell carcinoma metastasis when compared with free saracatinib. Researchers attributed these superior results to the specific, tumor-targeting nature of the novel nanoparticle delivery system.
To determine the effectiveness of saracatinib, the researchers used solvent evaporation to add the inhibitor to self-assembling nanoparticles. Wound healing and Transwell assays were assessed to determine cell migration and invasion, whereas Western blot, immunohistochemistry, or a combination thereof measured protein levels.
“We are convinced that with our novel drug delivery system, innovative and smart saracatinib nanomedicine can be developed for safe, efficient, and targeted cancer therapy,” the investigators concluded.
Disclosure: The study authors reported no conflicts of interest.